DEPOCYT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Depocyt, and when can generic versions of Depocyt launch?
Depocyt is a drug marketed by Pacira Pharms Inc and is included in one NDA.
The generic ingredient in DEPOCYT is cytarabine. There are fifteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the cytarabine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Depocyt
A generic version of DEPOCYT was approved as cytarabine by HIKMA on August 2nd, 1989.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DEPOCYT?
- What are the global sales for DEPOCYT?
- What is Average Wholesale Price for DEPOCYT?
Summary for DEPOCYT
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 123 |
Clinical Trials: | 79 |
Patent Applications: | 4,466 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DEPOCYT |
DailyMed Link: | DEPOCYT at DailyMed |
Recent Clinical Trials for DEPOCYT
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Kartos Therapeutics, Inc. | Phase 1/Phase 2 |
University of Florida | Phase 2 |
Medical College of Wisconsin | Phase 1 |
US Patents and Regulatory Information for DEPOCYT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pacira Pharms Inc | DEPOCYT | cytarabine | INJECTABLE, LIPOSOMAL;INJECTION | 021041-001 | Apr 1, 1999 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DEPOCYT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pacira Pharms Inc | DEPOCYT | cytarabine | INJECTABLE, LIPOSOMAL;INJECTION | 021041-001 | Apr 1, 1999 | ⤷ Sign Up | ⤷ Sign Up |
Pacira Pharms Inc | DEPOCYT | cytarabine | INJECTABLE, LIPOSOMAL;INJECTION | 021041-001 | Apr 1, 1999 | ⤷ Sign Up | ⤷ Sign Up |
Pacira Pharms Inc | DEPOCYT | cytarabine | INJECTABLE, LIPOSOMAL;INJECTION | 021041-001 | Apr 1, 1999 | ⤷ Sign Up | ⤷ Sign Up |
Pacira Pharms Inc | DEPOCYT | cytarabine | INJECTABLE, LIPOSOMAL;INJECTION | 021041-001 | Apr 1, 1999 | ⤷ Sign Up | ⤷ Sign Up |
Pacira Pharms Inc | DEPOCYT | cytarabine | INJECTABLE, LIPOSOMAL;INJECTION | 021041-001 | Apr 1, 1999 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for DEPOCYT
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Pacira Limited | DepoCyte | cytarabine | EMEA/H/C/000317 Intrathecal treatment of lymphomatous meningitis. In the majority of patients such treatment will be part of symptomatic palliation of the disease. |
Withdrawn | no | no | no | 2001-07-11 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for DEPOCYT
See the table below for patents covering DEPOCYT around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Brazil | PI0414551 | ⤷ Sign Up | |
Japan | 2007524589 | ⤷ Sign Up | |
Canada | 2277956 | PROCEDE SERVANT A UTILISER DES LIPIDES NEUTRES AFIN DE MODIFIER LA LIBERATION IN VIVO DEPUIS DES LIPOSOMES A VESICULES MULTIPLES (METHOD FOR UTILIZING NEUTRAL LIPIDS TO MODIFY IN VIVO RELEASE FROM MULTIVESICULAR LIPOSOMES) | ⤷ Sign Up |
Norway | 329401 | ⤷ Sign Up | |
Denmark | 1670433 | ⤷ Sign Up | |
Canada | 2538856 | FORMULATION PHARMACEUTIQUE TRANSDERMIQUE VISANT A REDUIRE LES RESIDUS SUR LA PEAU (TRANSDERMAL PHARMACEUTICAL FORMULATION FOR MINIMIZING SKIN RESIDUES) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for DEPOCYT
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3300601 | 2022C/528 | Belgium | ⤷ Sign Up | PRODUCT NAME: COMBINATIE VAN DAUNORUBICINE EN CYTARABINE; AUTHORISATION NUMBER AND DATE: EU/1/18/1308 20180827 |
3300601 | LUC00271 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; AUTHORISATION NUMBER AND DATE: EU/1/18/1308 20180827 |
1744764 | 2018/042 | Ireland | ⤷ Sign Up | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180823 |
3300601 | 2022027 | Norway | ⤷ Sign Up | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REG. NO/DATE: EU/1/18/1308 20180831 |
1744764 | 300960 | Netherlands | ⤷ Sign Up | PRODUCT NAME: COMBINATIE VAN DAUNORUBICINE EN CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827 |
2768484 | SPC/GB19/067 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REGISTERED: UK EU/1/18/1308(FOR NI) 20180827; UK PLGB 31626/0004 20180827 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |